Company insight Rapid molecular diagnostics
Though medical knowledge and technology continue apace, the presence of infectious diseases is not going anywhere. In response to that, it is important that PCR testing improves to limit the impact and reach of those diseases. Abacus Diagnostica is on the front line, developing and rolling out new and ever-more effi cient tests for its automated GenomEra CDX platform.
ever. Abacus Diagnostica has brought to the market CE-marked rapid SARS-CoV-2 RT-PCR tests for use with the GenomEra CDX system, which is an easy-to-use, reliable and affordable solution for daily molecular diagnostics. No special expertise nor dedicated PCR facilities are required, making the GenomEra CDX suitable for any kind of laboratory. Abacus Diagnostica reacted fast to the Covid-19 outbreak and in just a couple of months, developed a PCR test detecting two different targets of SARS-CoV-2. To respond to the concern over the upcoming flu season, Abacus developed a
A
s a result of the global pandemic, sensitive and rapid molecular diagnostics are more relevant than
multiplex test for the simultaneous detection of SARS-CoV-2, influenza A and B, and RSV. With the new SARS- CoV-2 variants in focus, Abacus recently launched a SARS-CoV-2 Variants of Concern (VoC) test. In addition to detecting all SARS-CoV-2 strains, the test detects the clinically important deletions and mutations present in the variant strains.
Abacus Diagnostica has already turned its eyes to the future, and continues to expand the product portfolio of rapid PCR tests that simplify the everyday infectious disease diagnostics. Interesting picks of the future portfolio include an expanded faecal panel, which detects the gastroenteritis-related norovirus (GI and
GII), rotavirus and adenovirus, as well as a test for whooping cough. These pathogens are associated with severe infections and hospitalisations among infants and young children, and are highly contagious, making rapid and reliable diagnostics desirable. In addition, the GenomEra product portfolio is about to grow with a rapid PCR test for malaria, which is one of the main causes of severe infections worldwide, and especially dangerous for children. With a wide and continuously growing CE IVD assay portfolio, GenomEra CDX is enabling molecular diagnostics when and where it is needed. ●
www.abacusdiagnostica.com
Practical Patient Care /
www.practical-patient-care.com
25
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59
